This study found that GC patients with high TMEM200A expression may be sensitive to All-trans Retinoic Acid, Cytarabine, Nilotinib, and Crizotinib, but may be resistant to AKT.inhibitor.VIII, Afatinib, Gefitinib, Lapatinib, and Metformin. The gene discussed is TMEM200A; the disease is gastric cancer.